Related Experiment Videos
Differential therapy of hypertensive heart disease
1Department of Medicine, University of Duesseldorf, Federal Republic of Germany.
Insights
Hypertensive heart disease involves cardiac complications of high blood pressure. Treatment aims to reverse myocardial hypertrophy and improve coronary reserve, though long-term prognostic benefits require further study.
Area of Science:
- Cardiology
- Hypertension Research
- Internal Medicine
Background:
- Hypertensive heart disease encompasses myocardial hypertrophy and coronary artery issues stemming from arterial hypertension.
- Cardiac complications significantly influence the prognosis of patients with hypertension.
- The progression to hypertensive heart failure is a critical concern.
Purpose of the Study:
- To investigate the reversal of myocardial hypertrophy and hypertensive small coronary artery disease as therapeutic goals in hypertensive heart disease.
- To assess the impact of reversing cardiac complications on the prognosis of arterial hypertension.
- To evaluate the effectiveness of antihypertensive drugs in addressing cardiac manifestations.
Main Methods:
- Review of existing evidence on the treatment of hypertensive heart disease.
- Analysis of the role of antihypertensive medications, including calcium channel blockers, ACE inhibitors, and sympatholytics.
- Examination of the clinical evidence for reversing myocardial hypertrophy versus small coronary artery disease.
Main Results:
- Evidence is conclusive that certain antihypertensive drugs can induce regression of myocardial hypertrophy.
- Clinical evidence for the reversal of hypertensive small coronary artery disease is currently lacking.
- The prognostic improvement from reversing hypertrophy remains to be determined.
Conclusions:
- Reversal of myocardial hypertrophy is an achievable therapeutic goal in hypertensive heart disease.
- Further research is needed to establish the efficacy of treatments for hypertensive small coronary artery disease.
- The ultimate impact of reversing cardiac hypertrophy on patient outcomes requires additional investigation.
Abstract:
Hypertensive damage to the target organ "heart" comprises the sum and interactions of the cardiac organ manifestations of arterial hypertension such as myocardial hypertrophy and disease of large and small coronary arteries. Because the prognosis of arterial hypertension is determined to a considerable extent by these cardiac complications, the aim of treatment of hypertensive heart disease is reversal of the myocardial hypertrophy in order to prevent later progression to hypertensive heart failure. A further goal of therapy is reversal of the hypertensive small coronary disease in order to improve the coronary reserve. Once the stage of hypertensive heart failure is reached, the principles of medical management of heart failure with digitalis, diuretics and angiotensin-converting enzyme inhibitors apply. Whereas the evidence that regression of hypertrophy can be induced by suitable antihypertensive drugs (calcium channel blockers of the dihydropyridine type, angiotensin-converting enzyme inhibitors and sympathicolytic substances) is practically conclusive, clinical evidence of reversal of the hypertensive disease of small coronary arteries has yet to be provided. Moreover, to what extent the prognosis of hypertensive heart disease can be improved by reversal of hypertrophy is still unknown.